loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Sun Pharma has received approval from the Brazilian Health Regulatory Agency

ICICIdirect Research 30 Jul 2026 DISCLAIMER

News: Sun Pharma has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a local partner in Brazil. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once-weekly dosing

View: The semaglutide injectable market in Brazil is approximately US$ 413 million (IQVIA, MAT June 2026). Given that Sun will be among the first few launchers, this can be a meaningful launch for Sun as this will strengthen its Emerging Market portfolio. It can also fetch decent margins.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere